Plus therapeutics completes dosing in cohort 4 of respect-lm phase 1 clinical trial of rhenium (¹⁸⁶re) obisbemeda in leptomeningeal metastases

Cohort 4 of the respect-lm phase 1 dose escalation trial is the first of 4 planned cohorts in part b; the company anticipates moving into cohort 5 following standard safety review
PSTV Ratings Summary
PSTV Quant Ranking